Prostate cancer: cardiovascular mortality and androgen deprivation.
Every treatment has unintended adverse effects, and androgen deprivation therapy (ADT) for prostate cancer is no exception. A flurry of reports has implicated ADT in increasing cardiovascular risk and mortality. In this regard, the 2009 study by Efstathiou and colleagues is a notable exception.
Basaria
Shehzad
S
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D012307:Risk Factors
D000726:Androgen Antagonists